ASCO 2017 delivered on the clinical highlights again this year, but cost of care and value were present also. Highlighted here are four important studies that report the latest in the cost and value discussion....
The Oncologic Drugs Advisory Committee (ODAC) met 4 times in 3 days earlier this month to make recommendations on 4 different oncology agents. That's a big week for ODAC. CAR-T, biosimilars, and more - what happened? Find out here....